Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). Up to $200.0M senior secured financing, with $65.0M drawn at closing on November 6, 2026.
Atea Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Up to $200.0M senior secured financing, with $65.0M drawn at closing on November 6, 2026
- Floating interest rate at the greater of prime plus 2.35% or 9.35%, increasing financing costs
- Interest-only payments for 48 months, with loans maturing November 1, 2031
- Additional tranches depend on BEM/RZR clinical, financing, development and commercialization milestones
- Substantially all assets, including intellectual property, secure the debt, with minimum cash and revenue covenants creating execution risk
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 points to Item 1.01 for details on Atea’s newly created financial obligation
- Investor impact depends on the referenced agreement’s payment terms, amount, maturity and purpose
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atea Pharmaceuticals, Inc. 8-K filings
Get the next AVIR 8-K as it lands
Follow AVIR for push alerts, or ask the research agent what this filing means.